Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. (28th November 2021)

• Record Type: Journal Article
• Authors: Liu, Chang; Wang, Miao; Xu, Changli; Li, Bo; Chen, Juxiang; Chen, Jianchun; Wang, Zhiwei
• Other Names: Lu Xiao-Jie Academic Editor.
• Is Part Of: Journal of immunology research. Volume 2021(2021)
• Publication Date: 2021-11-28
• Subjects: Immunology -- Periodicals; Immunology -- Research -- Periodicals; 616.07905
• DOI: 10.1155/2021/8970173
• Languages: English
• ISSNs: 2314-8861

Abstract

Abstract : The treatment of bone metastases is a thorny issue. Immunotherapy may be one of the few hopes for patients with unresectable bone metastases. Immune checkpoint inhibitors are the most commonly used immunotherapy drugs currently. In this review, the characteristics and interaction of bone metastases and their immune microenvironment were systematically discussed, and the relevant research progress of the immunological mechanism of tumor bone metastasis was reviewed. On this basis, we expounded the clinical application of immune checkpoint inhibitors for bone metastasis of common tumors, including non-small-cell lung cancer, renal cell carcinoma, prostate cancer, melanoma, and breast cancer. Then, the deficiencies and limitations in current researches were summarized. In-depth basic research on bone metastases and optimization of clinical treatment is needed.